1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Service, and Geography

Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Service, and Geography

  • May 2020
  • 125 pages
  • ID: 5894514
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

Asia Pacific Biopharmaceutical Contract Manufacturing Market to 2027 - COVID-19 Impact Analysis Regional Analysis and Forecast by Product and Service.
The biopharmaceutical contract manufacturing market in Asia Pacific is anticipated to reach US$ 4,997.46 Mn in 2027 from US$ 2,580.70 Mn in 2019. The market is projected to grow with a CAGR of 8.8% from 2020 to 2027.
The biopharmaceutical contract manufacturing market is growing primarily due to the increasing demand for biologics and increasing outsourcing by pharmaceutical companies in Asia Pacific.Increasing competition in the industry is likely to damage the growth of the market in the coming years.

Additionally, robust advancements in research and development activities, emerging markets, and consolidation in the pharmaceutical CMO industry are likely to increase the growth of the biopharmaceuticals contract manufacturing during the forecast period.
Contract manufacturing is the type of outsourcing where a company enters into an agreement or legal settlement with another manufacturing firm for products, parts, or components, which the company will then use in its production process to complete its product. Various biopharmaceutical companies manufacture antibodies, non-antibody scaffolds, recombinant proteins, fragments as well as DNA from different sources.
The contract manufacturing organization (CMO) offers numerous benefits to pharmaceutical companies, by reducing investments in facilities, drug development costs, which in turn improves net cash flow.Outsourcing is cheaper and increases the efficiency of manufacturing processes.

The rise of the CMOs was fueled by the increasing number of drug manufacturing failures.In the past, pharmaceutical companies had dedicated manufacturing facilities for innovative drugs in development.

However, to reduce the risk of overcapacities, the demand for manufacturing outsourcing has been rising continuously.
This new trend of outsourcing is resulting in many benefits to the CMOs in multiple Asian countries, such as Singapore, South Korea, India, and China.Many companies see growth opportunities in this sector.

For instance, Samsung Biologics, founded in 2011, with its massive mammalian cell capacity i.e., 360,000L, surpasses most established service providers. Singapore is also becoming a hot spot favored by many global companies considering outsourcing of bioprocessing. Wuxi Biologics has just started its operation of a new facility, which is the largest mammalian cell culture manufacturing facility that uses disposable bioreactors in the world. The facility uses 14x 2,000L and two 1,000L disposable bioreactors for late-phase clinical and commercial manufacturing. JHL Biotech’s Wuhan facility, which started operations in 2016, has a current capacity of ~10,000L and is also expanding. Furthermore, CMOs play crucial roles in providing additional capacities to mitigate the risk of supply shortages by offering additional sites for pharmaceutical companies with multisite supply strategies as well as backup capacities. For instance, some industry insiders in China, strongly believe that China can be a destination for this wave of outsourcing. According to BioPlan’s analyses of China’s biopharma facilities, over 90% of mid-scale and larger biopharmas are planning to expand their own facilities. For example, BeiGene, the company using Boehringer’s CMO services in Beijing, is also building a bio-manufacturing facility in Guangzhou. Thus, the above-mentioned factors are likely to boost the growth of the biopharmaceutical contract manufacturing market in Asia Pacific during the forecast period.
In 2019, the biologics segment held the largest market share in the biopharmaceutical contract manufacturing market in Asia Pacific.A significant boom has been witnessed in the contract manufacturing of biologics.

This can be attributed to difficulties in the production of a large-scale biologics in house.Moreover, the Beijing-based Autekbio, founded in 2011, was the first and one of the fully devoted CMOs to contract manufacturing of biologicals.

TaiMed Biologics Ibalizumab, the FDA-designated orphan drug, is manufactured by CMO WuXi PharmaTech. Hence, with the increasing demand for biologics, many companies are opting CMOs services to speed up the development process and lower production costs.
Considering the geographic and economical operations between Asian countries and China, the states are expected to witness the challenge of COVID-19.Due to this crisis, many contract manufacturers in India have restricted the production, which has affected its export revenues.

Additionally, COVID-19 may cause massive recalls of products resulting in massive problems for contract manufacturers in the region.
During the forecast period, the analytical and quality control segment estimated the highest CAGR in the market of 8.8% in 2019.CMOs provide a wide array of services ranging from cell cultivation to final product packaging. Increasing regulatory compliance, complex manufacturing process, and product integrity are driving the adoption of the services mentioned above offered by CMOs. Hence, the segment is anticipated to witness a significant growth during the forecast period.
Some of the significant secondary sources for biopharmaceutical contract manufacturing market included in the report are the World Health Organization (WHO) and the China Food and Drug Administration (CFDA).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on